Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations

J. Weng, Wendy Macfarlane, M. Lehto, H.F. Gu, L.M. Shepherd, S.A. Ivarsson, L. Wibell, T. Smith, L.C. Groop

Research output: Contribution to journalArticle

Abstract

The aim of this study was to examine the putative role of mutations in the insulin promoter 1 (IPF1) gene in early-onset diabetes. Methods. We carried out mutation screening of the IPF1 gene in 115 Scandinavian families with at least two members with onset of diabetes younger than 40 years. The allele frequencies were also tested in 183 unrelated patients with late-onset Type II (non-insulin-dependent) diabetes mellitus and in 92 non-diabetic control subjects. Results. Two novel IPF1 variants (G212R and P239Q) and one previously reported (D76N) IPF1 variant were identified in the 115 families (3.5 %). The D76N variant was found in one MODY3 family (S315fsinsA of HNF1a) and also in two families with late-onset Type II diabetes. The P239Q variant was identified in two families with early-onset diabetes including one with MODY3 (R272C of HNF 1a) and in three families with late-onset Type II diabetes. Despite the fact that the variants did not segregate completely with diabetes, the non-diabetic carriers of the IPF1 variants had increased blood glucose concentrations (p < 0.05) and reduced insulin:glucose ratios (p < 0.05) during an oral glucose tolerance test compared with non-diabetic family members without these variants. In addition, when the G212R and P239Q variants were expressed in cells without IPF1 i. e. . Nes2 y cells, both variants showed about a 50 % reduction in their ability to activate insulin gene transcription compared to wild-type IPF1, as measured by reporter gene assay. Conclusion/interpretation. Although mutations in the IPF-1 gene are rare in early- (3.5 %) and late-onset (2.7 %) Type II diabetes, they are functionally important and occur also in families with other MODY mutations.
Original languageEnglish
Pages (from-to)249-258
Number of pages10
JournalDiabetologia
Volume44
Issue number2
DOIs
Publication statusPublished - Feb 2001

Fingerprint

Mutation
Genes
Insulin
Type 2 Diabetes Mellitus
Aptitude
Maturity-Onset Diabetes of the Young, Type 4
Maturity-Onset Diabetes of the Young, Type 3
Glucose Tolerance Test
Reporter Genes
Gene Frequency
Blood Glucose
Glucose

Cite this

Weng, J., Macfarlane, W., Lehto, M., Gu, H. F., Shepherd, L. M., Ivarsson, S. A., ... Groop, L. C. (2001). Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations. Diabetologia, 44(2), 249-258. https://doi.org/10.1007/s001250051608
Weng, J. ; Macfarlane, Wendy ; Lehto, M. ; Gu, H.F. ; Shepherd, L.M. ; Ivarsson, S.A. ; Wibell, L. ; Smith, T. ; Groop, L.C. / Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations. In: Diabetologia. 2001 ; Vol. 44, No. 2. pp. 249-258.
@article{80a3c422a58542babf3b4ea5da0bf4d0,
title = "Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations",
abstract = "The aim of this study was to examine the putative role of mutations in the insulin promoter 1 (IPF1) gene in early-onset diabetes. Methods. We carried out mutation screening of the IPF1 gene in 115 Scandinavian families with at least two members with onset of diabetes younger than 40 years. The allele frequencies were also tested in 183 unrelated patients with late-onset Type II (non-insulin-dependent) diabetes mellitus and in 92 non-diabetic control subjects. Results. Two novel IPF1 variants (G212R and P239Q) and one previously reported (D76N) IPF1 variant were identified in the 115 families (3.5 {\%}). The D76N variant was found in one MODY3 family (S315fsinsA of HNF1a) and also in two families with late-onset Type II diabetes. The P239Q variant was identified in two families with early-onset diabetes including one with MODY3 (R272C of HNF 1a) and in three families with late-onset Type II diabetes. Despite the fact that the variants did not segregate completely with diabetes, the non-diabetic carriers of the IPF1 variants had increased blood glucose concentrations (p < 0.05) and reduced insulin:glucose ratios (p < 0.05) during an oral glucose tolerance test compared with non-diabetic family members without these variants. In addition, when the G212R and P239Q variants were expressed in cells without IPF1 i. e. . Nes2 y cells, both variants showed about a 50 {\%} reduction in their ability to activate insulin gene transcription compared to wild-type IPF1, as measured by reporter gene assay. Conclusion/interpretation. Although mutations in the IPF-1 gene are rare in early- (3.5 {\%}) and late-onset (2.7 {\%}) Type II diabetes, they are functionally important and occur also in families with other MODY mutations.",
author = "J. Weng and Wendy Macfarlane and M. Lehto and H.F. Gu and L.M. Shepherd and S.A. Ivarsson and L. Wibell and T. Smith and L.C. Groop",
year = "2001",
month = "2",
doi = "10.1007/s001250051608",
language = "English",
volume = "44",
pages = "249--258",
journal = "Diabetologia",
issn = "0012-186X",
number = "2",

}

Weng, J, Macfarlane, W, Lehto, M, Gu, HF, Shepherd, LM, Ivarsson, SA, Wibell, L, Smith, T & Groop, LC 2001, 'Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations', Diabetologia, vol. 44, no. 2, pp. 249-258. https://doi.org/10.1007/s001250051608

Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations. / Weng, J.; Macfarlane, Wendy; Lehto, M.; Gu, H.F.; Shepherd, L.M.; Ivarsson, S.A.; Wibell, L.; Smith, T.; Groop, L.C.

In: Diabetologia, Vol. 44, No. 2, 02.2001, p. 249-258.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations

AU - Weng, J.

AU - Macfarlane, Wendy

AU - Lehto, M.

AU - Gu, H.F.

AU - Shepherd, L.M.

AU - Ivarsson, S.A.

AU - Wibell, L.

AU - Smith, T.

AU - Groop, L.C.

PY - 2001/2

Y1 - 2001/2

N2 - The aim of this study was to examine the putative role of mutations in the insulin promoter 1 (IPF1) gene in early-onset diabetes. Methods. We carried out mutation screening of the IPF1 gene in 115 Scandinavian families with at least two members with onset of diabetes younger than 40 years. The allele frequencies were also tested in 183 unrelated patients with late-onset Type II (non-insulin-dependent) diabetes mellitus and in 92 non-diabetic control subjects. Results. Two novel IPF1 variants (G212R and P239Q) and one previously reported (D76N) IPF1 variant were identified in the 115 families (3.5 %). The D76N variant was found in one MODY3 family (S315fsinsA of HNF1a) and also in two families with late-onset Type II diabetes. The P239Q variant was identified in two families with early-onset diabetes including one with MODY3 (R272C of HNF 1a) and in three families with late-onset Type II diabetes. Despite the fact that the variants did not segregate completely with diabetes, the non-diabetic carriers of the IPF1 variants had increased blood glucose concentrations (p < 0.05) and reduced insulin:glucose ratios (p < 0.05) during an oral glucose tolerance test compared with non-diabetic family members without these variants. In addition, when the G212R and P239Q variants were expressed in cells without IPF1 i. e. . Nes2 y cells, both variants showed about a 50 % reduction in their ability to activate insulin gene transcription compared to wild-type IPF1, as measured by reporter gene assay. Conclusion/interpretation. Although mutations in the IPF-1 gene are rare in early- (3.5 %) and late-onset (2.7 %) Type II diabetes, they are functionally important and occur also in families with other MODY mutations.

AB - The aim of this study was to examine the putative role of mutations in the insulin promoter 1 (IPF1) gene in early-onset diabetes. Methods. We carried out mutation screening of the IPF1 gene in 115 Scandinavian families with at least two members with onset of diabetes younger than 40 years. The allele frequencies were also tested in 183 unrelated patients with late-onset Type II (non-insulin-dependent) diabetes mellitus and in 92 non-diabetic control subjects. Results. Two novel IPF1 variants (G212R and P239Q) and one previously reported (D76N) IPF1 variant were identified in the 115 families (3.5 %). The D76N variant was found in one MODY3 family (S315fsinsA of HNF1a) and also in two families with late-onset Type II diabetes. The P239Q variant was identified in two families with early-onset diabetes including one with MODY3 (R272C of HNF 1a) and in three families with late-onset Type II diabetes. Despite the fact that the variants did not segregate completely with diabetes, the non-diabetic carriers of the IPF1 variants had increased blood glucose concentrations (p < 0.05) and reduced insulin:glucose ratios (p < 0.05) during an oral glucose tolerance test compared with non-diabetic family members without these variants. In addition, when the G212R and P239Q variants were expressed in cells without IPF1 i. e. . Nes2 y cells, both variants showed about a 50 % reduction in their ability to activate insulin gene transcription compared to wild-type IPF1, as measured by reporter gene assay. Conclusion/interpretation. Although mutations in the IPF-1 gene are rare in early- (3.5 %) and late-onset (2.7 %) Type II diabetes, they are functionally important and occur also in families with other MODY mutations.

U2 - 10.1007/s001250051608

DO - 10.1007/s001250051608

M3 - Article

VL - 44

SP - 249

EP - 258

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 2

ER -